



AP7 Rec'd PCT/PTO 08 FEB 2006

PCT

4.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket: KAWAMURA=69

In re Application of:

Ryoichi KAWAMURA

Appln. No.: 10/536,963

Filed: May 31, 2005

For: NOVEL MEDICAMENT FOR
AMELIORATING NEUROTRANS-
MISSION DYSFUNCTION...

Conf. No.: 6392

Art Unit: Not Yet Known

Examiner: Not Yet Known

Washington D.C.

February 8, 2006

INFORMATION DISCLOSURE STATEMENT [IDS]

Honorable Commissioner for Patents
U.S. Patent and Trademark Office
Customer Service Window
Randolph Building, Mail Stop Amendment
401 Dulany Street
Alexandria, VA 22314

Sir:

This Information Disclosure Statement is submitted in accordance with 37 CFR §§1.97, 1.98, and it is requested that the information set forth in this statement and in the listed documents be considered during the pendency of the above-identified application, and any other application relying on the filing date of the above-identified application or cross-referencing it as a related application.

[X] 1. This IDS should be considered, in accordance with 37 CFR §1.97, as it is filed:

[] A. within three months of the filing date of the above-identified national application or within three months of the entry into the national stage of the above-identified international application.

[X] B. before the mailing date of a first office action on the merits or before the mailing of a first Office action after the filing of a Request for Continued Examination under 37 CFR §1.114; or

☐ C. after (A) and (B) above, but before final rejection or allowance, and Applicant has made the necessary certification (box "i" below) or paid the necessary fee (box "ii" below):

☐ i. Counsel certifies that, upon information and belief, each item of information listed herein either was

☐ (a) first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS; or

☐ (b) not cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of undersigned after making reasonable inquiry, not known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this IDS.

☐ ii. Credit Card Payment Form, PTO-2038, is attached authorizing payment of the fee set forth in 37 CFR §1.17(p), presently believed to be \$180. If the enclosed payment is incorrect, please charge any additional fees or credit any overpayment to Deposit Account No. 02-4035 of the undersigned.

☐ D. after (A), (B) and (C) above, but before payment of the issue fee: Applicant states as follows under 37 CFR §1.97(e) for consideration of this IDS, that, upon information and belief, each item of information listed herein either was

☐ (a) first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS; or

☐ (b) not cited in a communication from a foreign patent office in a counterpart foreign

application and, to the knowledge of the undersigned after making reasonable inquiry, not known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this IDS.

Credit Card Payment Form, PTO-2038, is attached authorizing payment of the fee set forth in 37 CFR §1.17(p), presently believed to be \$180. If the enclosed payment is incorrect, please charge any additional fees or credit any overpayment to Deposit Account No. 02-4035 of the undersigned.

[X] 2. In accordance with 37 CFR §1.98, this IDS includes a list (e.g., form BN/SB/08A/B) of all patents, publications, or other information submitted for consideration by the office, either incorporated into this IDS or as an attachment hereto. Other than U.S. patent(s) and/or published U.S. application(s), which 37 CFR §1.98(a)(2)(ii) does not require to be filed unless specifically required by the Office, a copy of each document listed is attached, except as explained below:

[] A. Document(s) _____ is/are deemed substantially cumulative to document(s) _____, and, in accordance with 37 CFR §1.98(c), a copy of each of the former document(s) is not enclosed.

[] B. Certain documents were previously cited by or submitted to the Office in the following prior application(s), which are relied upon under 35 U.S.C. 120:

(insert serial numbers and filing dates of prior applications)

Applicant identifies these documents by attaching hereto copies of the forms PTO-892, PTO-1449, PTO/SB/08a and/or PTO/SB/08b (or their BN form equivalents) from the files of the prior application(s) or a fresh BN/SB/08A and/or BN/SB/08B listing these documents, and request that they be considered and made of record in accordance with 37 CFR §1.98(d). Per 37 CFR §1.98(d), copies of these documents need not be filed in this application.

[X] 3. Documents AA, AC, AE, AG, AQ, AR, AS, AT, AU are not in the English language. In accordance with 37 CFR §1.98(a)(3), Applicant states:

[X] An English translation of each document AA, AC, AE, AG, AQ, AR, AS, AT, AU (or of the pertinent portions thereof), or a copy of an English-language abstract (or claim) is enclosed.

[X] For documents AA, AC, AE, AG, a corresponding English-language patent or published application is included on the accompanying Form BN/SB/08A, with a line drawn in the margin connecting the non-English-language document with its corresponding English-language document.

[] A concise explanation of the relevance of document(s) _____ is found in the attached _____ search report (see reply to Comment 68 in the preamble to the final rules; 1135 OG 13 at 20).

[] A concise explanation of the relevance of document(s) _____ is set forth as follows:

[X] A concise explanation of the relevance of the following documents can be found of the specification:

Doc. #	Page #-Line #
AA	P8-L18
AN	P10-L5
AO	P2-L11; P3-L8; P4-L5; P4-L18; P5-L24.
AP	P5, L1; P5, L10; P5-L17;
AQ	P6-L19
AR	P6-L21
AS	P7-L3
AT	P7-L9
AU	P7-L18
AV	P9-L15
AW	P9-L19

Doc. #	Page #-Line #
AX	P9-L23
AY	P9-L24
AZ	P10-L3

[] A concise explanation of the relevance of document(s) _____ can be found on the attached sheet.

[X] 4. No explanation of relevance is necessary for documents in the English language (see reply to Comments 67 and 68 in the preamble to the final rules; 1135 OG 13 at 20).


[X] 5. Other information being provided for the examiner's consideration follows:

PCT Notification of Transmittal of Copies of
Translation of the International Preliminary
Examination Report mailed May 26, 2005

6. In accordance with 37 CFR §§1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in 37 CFR §1.56(b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant reserves the right to prove that the date of publication is in fact different.

Respectfully submitted,
BROWDY AND NEIMARK
Attorneys for Applicant(s)

By:


Sheridan Neimark
Registration No. 20,520

SN:ma
624 Ninth Street, N.W., Suite 300
Washington, D.C. 20001-5303
Telephone: (202) 628-5197
Facsimile: (202) 737-3528
G:\bn\A\aoyb\KAWAMURA69\pto\IDS-08Feb06.doc

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 3

Complete if Known

Application Number	10/536,963
Filing Date	May 31, 2005
First Named Inventor	Ryoichi KAWAMURA
Group Art Unit	Not Yet Known
Examiner Name	Not Yet Known
Attorney Docket Number	KAWAMURA=69

U.S. PATENT DOCUMENTS


Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Number Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	AA	WO 00/31131 A1	02-06-2000	T. AOYAMA et al.		X
	AB	EP 1 132 492 A1	09-12-2001	M. HIRASHIMA et al.		
	AC	WO 02/076492 A1	10-03-2002	M. HIRASHIMA et al.		X
	AD	EP 1 374 887 A1	01-02-2004	M. HIRASHIMA et al.		
	AE	WO 02/092121 A1	11-21-2002	M. HIRASHIMA et al.		X
	AF	EP 1 393 740 A1	03-03-2004	M. HIRASHIMA et al.		
	AG	WO 03/029469 A1	04-10-2003	S. KAMINAKA et al.		X
	AH	EP 1 437 410 A1	07-14-2004	S. KAMINAKA et al.		

Examiner
SignatureDate
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2

of 3

Complete Known

Application Number	10/536,963
Filing Date	May 31, 2005
First Named Inventor	Ryoichi KAWAMURA
Group Art Unit	Not Yet Known
Examiner Name	Not Yet Known
Attorney Docket Number	KAWAMURA=69


NON PATENT LITERATURE DOCUMENTS / OTHER INFORMATION

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	AI	Jae-Ryong KIM et al., "Oxidation of Proteinaceous Cysteine Residues by Dopamine-Derived H ₂ O ₂ in PC12 Cells", <u>Archives of Biochemistry and Biophysics</u> , Vol. 397, No. 2, pp. 414-423, January 15, 2002.	
	AJ	Volker MOSTERT, "Selenoprotein P: Properties, Functions, and Regulations", <u>Archives of Biochemistry and Biophysics</u> , Vol. 376, No. 2, pp. 433-438, April 15, 2000,	
	AK	Yoshiro SAITO et al., "Selenoprotein P: Its Structure and Functions", <u>Journal of Health Science</u> , Vol. 46, No. 6, pp. 409-413, 2000.	
	AL	Xiaoguang YANG et al., "Synthesis and secretion of selenoprotein P by cultured rat astrocytes", <u>Biochimica et Biophysica Acta</u> , 1474, pp. 390-396, 2000.	
	AM	Berta ALSINA et al., "Disruption of selenoprotein biosynthesis affects cell proliferation in the imaginal discs and brain of <i>Drosophila melanogaster</i> ", <u>Journal of Cell Science</u> , Vol. 112, pp. 2875-2884, August 1999.	
	AN	Jun YAN et al., "Purification from Bovine Serum of a Survival-Promoting Factor for Cultured Central Neurons and Its Identification as Selenoprotein-P", <u>Journal of Neuroscience</u> , Vol. 18, No. 21, pp. 8682-8691, November 1, 1998.	
	AO	Ed. by Mori et al., "Cerebral Nerve Science Illustrated", Yodasha, pp. 138-144.	
	AP	Ed. by Taniguchi et al., "Physiological Action of NO and Diseases". Yodasha, pp. 181-185.	
	AQ	Web Site Merck Manual, 17 th Edition (In Japanese) - Corresponding URL in English: http://www.merck.com/pubs .	X
	AR	Ed. by Manabe et al., "How to Carry Out Cerebral Nerve Study", Yadosha, pp. 158-162.	X
	AS	"Grand Medical Dictionary", CD-ROM, Nanzando.	X
	AT	"Z-338, <u>New Current</u> ", Vol. 13, No. 20, pp. 26-29, 2002	X

Examiner
SignatureDate
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.



BN/SB/08A/B

Substitute for form 1449A/PTO

Complete Known

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3

of 3

Application Number 10/536,963

Filing Date May 31, 2005

First Named Inventor Ryoichi KAWAMURA

Group Art Unit Not Yet Known

Examiner Name Not Yet Known

Attorney Docket Number KAWAMURA=69

NON PATENT LITERATURE DOCUMENTS / OTHER INFORMATION

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	AU	"Tacrine", <u>New Current</u> , Vol. 7, No. 2, pp. 2-7, 1996.	X
	AV	Kristina E. HILL et al., "Seleoprotein P: Recent Studies in Rats and in Humans", <u>Biomedical and Environmental Sciences</u> , Vol. 10, pp. 198-208, 1997.	
	AW	Kristina E. HILL et al., "Conserved nucleotide sequences in the open reading frame and 3' untranslated region of selenoprotein P mRNA", <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 90, No. 2, pp. 537-541, January 1993.	
	AX	Yoshiro SAITO et al., "Selenoprotein P in Human Plasma as an Extracellular Phospholipid Hydroperoxide Glutathione Peroxidas", <u>Journal of Biological Chemistry</u> , Vol. 274, No. 5, pp. 2866-2871, January 29, 1999.	
	AY	Gavin E. ARTEEL et al., "Protection by Selenoprotein P in Human Plasma against Peroxynitrite-Mediated Oxidation and Nitration", <u>Biol. Chem.</u> , Vol. 379, pp. 1201-1205, August/September 1998.	
	AZ	Raymond F. BURK et al., "Response of rat selenoprotein P to selenium administration and fate of its selenium", <u>American Physiological Society</u> , 261(1 Pt1), pp. E26-E30, 1991.	

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.